Sequenta

Sequenta

Sequenta

is dedicated to improving patient care in diseases mediated by immune cells. Our ClonoSIGHT™ test for MRD in lymphoid cancers launched in 2013.
Founded
2008
Raised
$41.5M
Follow us
Alexa global traffic share